REL-1017(艾司美沙酮)作为重性抑郁障碍患者辅助治疗:一项2a期随机双盲试验
本研究为7天2a期多中心随机双盲安慰剂对照三臂试验,纳入当前抑郁发作对1至3种标准抗抑郁药治疗无效的重性抑郁障碍患者,随机分配至安慰剂组(N=22)、REL-1017 25 mg/日组(N=19)或50 mg/日组(N=21)。结果显示患者仅出现轻或中度一过性不良事件,未见解离或拟精神病效应、阿片效应或戒断症状体征;两个REL-1017剂量组第4天MADRS评分改善持续至第7天(末次给药)和第14天(末次给药后7天),效应量为0.7至1.0。结论提示REL-1017可能具有快速且持久的抗抑郁效应,但需在更大规模及更长疗程的试验中确认。
要点
- REL-1017 25 mg/日与50 mg/日组第4天MADRS评分改善持续至第7天及第14天,效应量0.7至1.0。
- 患者仅出现轻或中度一过性不良事件,未见解离、拟精神病、阿片效应或戒断症状体征。
- 作者认为REL-1017可能具有快速且持久的抗抑郁效应,需在更大规模及更长疗程试验中确认。
核心结论
- 作者认为该试验显示REL-1017具有有利的安全性、耐受性和药代动力学特征,并提示与安慰剂相比,REL-1017可能对标准抗抑郁治疗应答不充分的重性抑郁障碍患者具有快速且持久的抗抑郁效应。
- 作者指出这些结果需在更大规模及更长疗程的试验中确认。
研究设计与样本
- 7天2a期多中心随机双盲安慰剂对照三臂试验,评估REL-1017 25 mg或50 mg口服每日一次的安全性、耐受性、药代动力学和疗效。
- 患者按1:1:1随机分配至安慰剂组(N=22)、REL-1017 25 mg/日组(N=19)或REL-1017 50 mg/日组(N=21),全部62例随机分配患者纳入全分析集。
- 纳入当前重性抑郁发作对1至3种标准抗抑郁药治疗无效的重性抑郁障碍患者。
主要发现
- 患者出现轻或中度一过性不良事件,未见解离或拟精神病效应、阿片效应或戒断症状体征的证据。
- 两个REL-1017剂量组第4天MADRS评分改善持续至第7天(末次给药)和第14天(末次给药后7天),效应量为0.7至1.0。
- 安全性量表包括4项阳性症状评定量表(评估拟精神病症状)、临床医生用解离状态量表(评估解离症状)、临床阿片戒断量表(评估戒断体征和症状)及哥伦比亚自杀严重程度评定量表(评估自杀倾向)。
关键数值与推荐
- 主要疗效终点为蒙哥马利-Å斯伯格抑郁评定量表(MADRS)评分。
- REL-1017 25 mg或50 mg口服每日一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出这些结果需在更大规模及更长疗程的试验中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: The purpose of this study was to examine the effects of REL-1017 (esmethadone), a novel N-methyl-d-aspartate receptor (NMDAR) channel blocker, in patients with major depressive disorder who failed to benefit from one to three standard antidepressant treatments in their current major depressive episode. Methods: A 7-day phase 2 multicenter randomized double-blind placebo-controlled trial, comprising three arms, was conducted to assess the safety, tolerability, pharmacokinetics, and efficacy of two dosages of REL-1017 (25 mg or 50 mg orally once a day). Patients were randomly assigned in a 1:1:1 ratio to placebo (N=22), REL-1017 25 mg/day (N=19), or REL-1017 50 mg/day (N=21). Safety scales included the 4-item Positive Symptom Rating Scale for psychotomimetic symptoms, the Clinician-Administered Dissociative States Scale for dissociative symptoms, the Clinical Opiate Withdrawal Scale for withdrawal signs and symptoms, and the Columbia-Suicide Severity Rating Scale for suicidality. The primary efficacy endpoint was the Montgomery-Åsberg Depression Scale (MADRS) score. All 62 randomly assigned patients were included in the full analysis set population analysis. Results: Patients experienced mild or moderate transient adverse events and no evidence of dissociative or psychotomimetic effects, opioid effects, or withdrawal signs and symptoms. The improvement in MADRS score shown on day 4 in both of the REL-1017 dosage groups was sustained through day 7 (last dose) and day 14 (7 days after the last dose), with effect sizes from 0.7 to 1.0. Conclusions: This trial showed favorable safety, tolerability, and pharmacokinetic profiles and suggests that REL-1017 may have rapid and sustained antidepressant effects compared with placebo in patients with inadequate responses to antidepressant treatments. These results will need confirmation in larger and longer trials.
引用
- Fava M, Stahl S, Pani L, et al. REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. Am J Psychiatry. 2021. PMID: 34933568. doi:10.1176/appi.ajp.2021.21020197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。